Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable ...

BERLIN, June 3 (Reuters) - Eli Lilly will halve its originally planned investment of €2.3 billion ($2.67 billion) in Germany, ...

By Padmanabhan Ananthan June 3 (Reuters) - Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its ...

CNBC’s Angelica Peebles sits down with Lilly’s President of Oncology and Head of Business Development at the largest global ...

Macro strategist Jordi Visser delivered a striking observation on a recent episode of The Pomp Podcast with Anthony Pompliano ...

SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own.

David Ricks was addressing the pharmaceutical titan's latest hot product.

Eli Lilly & Co. struck a deal worth up to $1.9 billion with privately held biotech Ascidian Therapeutics Inc. to develop treatments for rare kidney diseases, expanding the obesity drugmaker’s push ...

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered ...

By Sriparna Roy May 28 (Reuters) - CVS Health will restore Eli Lilly's weight-loss injection Zepbound to its list of covered ...

Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through ...